The healthcare industry is one of the most critical industries in the world. One of the successful individuals in the health sector is Scott Rocklage. Scott has vast experience in healthcare management and strategic leadership responsibilities. Due to these skills, the FDA has approved three of his drugs (Teslascan®, Omniscan™, and Cubicin®).
In 2003, Scott joined 5 AM Ventures as a partner and later became a managing partner the following year. Scott Rocklage served as the CEO and chairperson of Nycomed Interventional and held several positions at Catalytica and Salutar. Currently, he acts as the chair of Relypsa, Achaogen, and semprus boards. He is also a member of the Council of WaveRx and other institutes.
Scott Rocklage schooled at the University of California, Berkeley for his bachelor’s degree. For his Ph.D. in the same field, he attended Massachusetts Institute of Technology. You can find Dr. Scott in the Waltham, MA office.
How did Dr. Scott come up with the idea of his business?
As mentioned earlier, Dr. Scott line of business is science based. The venture capital firm called 5 AM Ventures since it is in the startup business, which is still considered early stage, so 5 AM suits it since it is early.
How Dr. Scott typical day is like and how he ensures it is productive
According to him, he does not have a regular day. He says his days are different. He spends some days learning new areas of life science, while others are spent working with portfolio company’s leaders and others he prepares and attends board meetings. Read more: Scott Racklage | Crunchbase
How Dr. Scott brings ideas to life
He collaborates with other entrepreneurs to help them in developing their ideas into potential means of treating undiscovered medical needs. These innovators include physicians, scientists, or business executives.
The trend that excites Dr. Scott the most
The idea and need of being able to target specific genotypes and mutations to treat cancer in unique ways excite him. It has led to extending life spans and saving lives, and it will result in improvements in the future.
Learn more about Scott Rocklage: http://people.equilar.com/bio/scott-rocklage-cidara-therapeutics-/salary/913398#.WWaMA9PytTY